Repurposing of Rutan showed effective treatment for COVID-19 disease
Shavkat Salikhov, Ibrokhim Y. Abdurakhmonov, Yuliya I. Oshchepkova, Jamolitdin F. Ziyavitdinov, Nodir Sh. Berdiev, Haji Akber Aisa, Jingshan Shen, Yechun Xu, H. Eric Xu, Xiangrui Jiang, Leike Zhang, Н. Л. Выпова, Dilshod Sh. Allaberganov, Nigora A. Tagayalieva, Erkin Musabaev, Gulnara A. Ibadova, Ilxom B. Rajabov, Lyubov M. Lokteva
Abstract
), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals' organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children. Clinical Trial Registration: ClinicalTrials.gov, ID NCT05862883.